From acute pancreatitis to end-organ injury: Mechanisms of acute lung injury

Surgical Infections

Volumn 8, Issue 1, 2007, Pages 107-120

  De Campos, Tercio ^a   Deree, Jessica ^a   Coimbra, Raul ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LUNG INJURY; ACUTE PANCREATITIS; ADULT RESPIRATORY DISTRESS SYNDROME; HUMAN; IMMUNOMODULATION; INCIDENCE; INFLAMMATORY DISEASE; MEDICAL LITERATURE; MEDLINE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

ACUTE DISEASE; CYTOKINES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION MEDIATORS; MICROCIRCULATION; MULTIPLE ORGAN FAILURE; PANCREAS; PANCREATITIS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 34247167091     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.011     Document Type: Review

References (146)

1. Bradley EL III. A clinically based classification system for acute pancreatitis: Summary of the International Symposium on Acute Pancreatitis, Atlanta, Ga., September 11 through 13, 1992. Arch Surg 1993;128:586-590.
2. Werner J, Hartwig W, Uhl W, et al. Useful markers for predicting severity and monitoring progression of acute pancreatitis. Pancreatology 2003;3:115-127.
3. Toouli J, Brooke-Smith M, Bassi C, et al. Guidelines for the management of acute pancreatitis. J Gastroenterol Hepatol 2002;17:15-39.
4. Werner J, Feuerbach S, Uhl W, Buchler MW. Management of acute pancreatitis: From surgery to interventional intensive care. Gut 2005;54:426-436.
5. Bockman DE. Microvasculature of the pancreas: Relation to pancreatitis. Int J Pancreatol 1992;12:11-21.
6. Clancy TE, Benoit EP, Ashley SW. Current management of acute pancreatitis. J Gastrointest Surg 2005;9:440-452.
7. Jacobs ML, Daggett WM, Civette JM, et al. Acute pancreatitis: Analysis of factors influencing survival. Ann Surg 1977;185:43-51.
8. Shields CJ, Winter DC, Redmond HP. Lung injury in acute pancreatitis: Mechanisms, prevention, and therapy. Curr Opin Crit Care 2002;8:158-163.
9. Steer ML. Early events in acute pancreatitis. Baillieres Best Pract Res Clin Gastroenterol 1999;13:213-225.
10. Mano AM de la, Sevillano S, Manso MA, et al. Cholecystokinin blockade alters the systemic immune response in rats with acute pancreatitis. Int J Exp Pathol 2004;85:75-84.
11. Sevillano S, Mano AM de la, Manso MA, et al. N-Acetykysteine prevents intra-acinar oxygen free radical production in pancreatic duct obstruction-induced acute pancreatitis. Biochim Biophys Acta 2003;1639:177-184.
12. Gorelick FS, Otani T. Mechanisms of intracellular zymogen activation. Baillieres Best Pract Res Clin Gastroenterol 1999;13:227-240.
13. Steer ML. The early intra-acinar cell events which occur during acute pancreatitis. Pancreas 1998;17:31-37.
14. Lerch MM, Saluja AK, Dawra R, et al. The effect of choloroquine administration on two experimental models of acute pancreatitis. Gastroenterology 1993;104:1768-1779.
15. Hofbauer B, Saluja AK, Lerch MM, et al. Intra-acinar cell activation of trypsinogen during caerulein-induced pancreatitis in rats. Am J Physiol 1998;275: G352-G362.
16. Long J, Song N, Liu XP, et al. Nuclear factor-kappaB activation on the reactive oxygen species in acute necrotizing pancreatitic rats. World J Gastroenterol 2005;11:4277-4280.
17. Yamauchi J, Shibuya K, Sunamura M, et al. Cytokine modulation in acute pancreatitis. J Hepatobiliary Pancreat Surg 2001;8:195-203.
18. Sunamura M, Yamauchi J, Shibuya K, et al. Pancreatic microcirculation in acute pancreatitis. J Hepatobiliary Pancreat Surg 1998;5:62-68.
19. Zhou ZG, Chen YD, Sun W, Chen Z. Pancreatic microcirculatory impairment in experimental acute pancreatitis in rats. World J Gastroenterol 2002;8: 933-936.
20. Foitzik T, Eibl G, Hotz B, et al. Persistent multiple organ microcirculatory disorders in severe acute pancreatitis: Experimental findings and clinical implications. Dig Dis Sci 2002;47:130-138.
21. Menger MD, Bonkhoff H, Vollmar B. Ischemia/ reperfusion-induced pancreatic microvascular injury: An intravital fluorescence microscopic study. Dig Dis Sci 1996;41:823-830.
22. Menger MD, Plusczyk T, Vollmar B. Microcirculatory derangements in acute pancreatitis. J Hepatobiliary Pancreat Surg 2001;8:187-194.
23. Cuzzocrea S, Mazzon E, Dugo L, et al. Absence of endogenous interleukin-6 enhances the inflammatory response during acute pancreatitis induced by cerulein in mice. Cytokine 2002;18:274-285.
24. Granger DN, Kubes P. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994;55:662-675.
25. Lall RN, Loomis W, Melbostad H, et al. Phosphodiesterase inhibition attenuates stored blood-induced neutrophil activation: A novel adjunct to blood transfusion. J Am Coll Surg 2006;202:10-17.
26. Marshall JC. Neutrophils in the pathogenesis of sepsis. Crit Care Med 2005;33(Suppl):S502-S505.
27. Coimbra R, Loomis W, Melbostad H, et al. LPS-stimulated PMN activation and proinflammatory mediator synthesis is downregulated by phosphodiesterase inhibition: Role of pentoxifylline. J Trauma 2004;57:1157-1163.
28. Hartwig W, Jimenez RE, Fernandez-del Castillo C, et al. Expression of the adhesion molecules Mac-1 and L-selecrin on neutrophils in acute pancreatitis is protease- and complement-dependent. Ann Surg 2001;233:371-378.
29. Gukovskaya AS, Vaquero E, Zaninovic V, et al. Neutrophils and NADPH oxidase mediate intrapancreatic trypsin activation in murine experimental acute pancreatitis. Gastroenterology 2002;122:974-984.
30. Yagci G, Gul H, Simsek A, et al. Beneficial effects of N-acetylcysteine on sodium taurocholate-induced pancreatitis in rats. J Gastroenterol 2004;39:268-276.
31. Yang R, Uchiyama T, Alber SM, et al. Ethyl pyruvate ameliorates distant organ injury in a murine model of acute necrotizing pancreatitis. Crit Care Med 2004;32:1453-1459.
32. Choi OS, Park SJ, Seo SW, et al. The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, lovastatin (statin) ameliorates CCK-induced acute pancreatitis in rats. Biol Pharm Bull 2005;28:1394-1397.
33. Kyriakides C, Jasleen J, Wang Y, et al. Neutrophils, not complement, mediate the mortality of experimental hemorrhagic pancreatitis. Pancreas 2001;22: 40-46.
34. Chen X, Ji B, Han B, et al. NF-kappaB activation in pancreas induces pancreatic and systemic inflammatory response. Gastroenterology 2002;122:448-457.
35. Norman JG, Fink GW, Franz MG. Acute pancreatitis induces intrapancreatic tumor necrosis factor gene expression. Arch Surg 1995;130:966-970.
36. Bhatia M, Brady M, Shokuhi S, et al. Inflammatory mediators in acute pancreatitis. J Pathol 2000;190: 117-125.
37. Altavilla D, Cainazzo MM, Squadrito F, et al. Tumor necrosis factor-alpha as a target of melacortins in hemorrhagic shock in the anesthetized rat. J Cardiovasc Pharmacol 1998;124:1587-1590.
38. Norman J. The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998;175:76-83.
39. Hughes CB, Henry J, Kotb M, et al. Up-regulation of TNF alpha mRNA in the rat spleen following induction of acute pancreatitis. J Surg Res 1995;59:687-693.
40. de Beaux AC, Goldie AS, Ross JA, et al. Serum concentrations of inflammatory mediators related to organ failure in patients with acute pancreatitis. Br J Surg 1996;83:349-353.
41. Scholmerich J. Interleukins in acute pancreatitis. Scand J Gastroenterol 1996;219:37-42.
42. Granger J, Remick D. Acute pancreatitis: Models, markers, and mediators. Shock 2005;24,Suppl1: 45-51.
43. Fink GW, Norman JG. Specific changes in the pancreatic expression of the interleukin-1 family of genes during experimental acute pancreatitis. Cytokine 1997;9:1023-1027.
44. Song M, Kellum, JA. Interleukin-6. Crit Care Med 2005;33(12 Suppl):S463-S465.
45. Cohen J. The immunopathogenesis of sepsis. Nature 2002;420:885-891.
46. Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-239.
47. Leser HG, Gross V, Scheibenbogen C, et al. Elevation of serum interleukin-6 concentration precedes acute phase response and reflects severity in acute pancreatitis. Gastroenterology 1991;101:782-785.
48. Remick DG, Bolgos GR, Siddiqui J, et al. Six at six: Interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002;17: 463-467.
49. Kasama T, Strieter RM, Lukacs NW, et al. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994;152:3559-3569.
50. Scumpia PO, Moldawer LL. Biology of interleukin-10 and its regulatory roles in sepsis syndromes. Crit Care Med 2005;33(12 Suppl):S468-471.
51. Seitz M, Loetscher P, Dewald B, et al. Interleukin-10 differentially regulates cytokine inhibitor and chemokine release from blood mononuclear cells and fibroblasts. Eur J Immunol 1995;25: 1129-1132.
52. Pezzilli R, Billi P, Miniero R, Barakat B. Serum interleukin-10 in human acute pancreatitis. Dig Dis Sci 1997;42:1469-1472.
53. Lo CJ, Fu M, Cryer HG. Interleukin 10 inhibits alveolar macrophage production of inflammatory mediators involved in adult respiratory distress syndrome. J Surg Res 1998;79:179-184.
54. Armstrong L, Milla AB. Relative production of tumour necrosis factor alpha and interleukin 10 in adult respiratory distress syndrome. Thorax 1997;52: 442-446.
55. Remick DG. Interleukin-8. Crit Care Med 2005;33(12 Suppl):S466-S467.
56. Rollins BJ. Chemokines. Blood 1997;90:909-928.
57. Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000;95:3032-3043.
58. Braun RK, Franchini M, Erard F, et al. Human peripheral-blood eosinophils produce and release interleukin-8 on stimulation with calcium ionosphere. Eur J Immunol 1993;23:956-960.
59. Hack CE, Hart M, van Schijndel RJ, et al. Interleukin-8 in sepsis: Relation to shock and inflammatory mediators. Infect Immun 1992;60:2835-2842.
60. Michetti C, Coimbra R, Hoyt DB, et al. Pentoxifylline reduces acute lung injury in chronic endotoxemia. J Surg Res 2003;115:92-99.
61. Kald B, Kald A, Ihse I, Tagesson C. Release of platelet-activating factor in acute experimental pancreatitis. Pancreas 1993;8:440-442.
62. Zhou W, Levine BA, Olson MS. Platelet activating factor: A mediator of pancreatic inflammation during cerulein stimulation. Am J Pathol 1993;142: 1504-1512.
63. Konturek SJ, Dembinski A, Konturek PJ, et al. Role of platelet activating factor in pathogenesis of acute pancreatitis in rats. Gut 1992;33:1268-1274.
64. Nagase T, Ishii S, Kume K, et al. Platelet-activating factor mediates acid-induced lung injury in genetically engineered mice. J Clin Invest 1999;104:1071-1076.
65. Adams DH, Nash GB. Disturbance of leucocyte circulation and adhesion to the endothelium as factors in circulatory pathway. Br J Anaesth 1996;77:17-31.
66. Roebuck KA, Finnegan A. Regulation of intercellular adhesion molecule-1 (CD54) gene expression. J Leukoc Biol 1999;66:876-888.
67. Steer ML. Relationship between pancreatitis and lung diseases. Respir Physiol 2001;128:13-16.
68. Bhatia M, Moochhala S. Role of inflammatory mediators in the pathophysiology of acute, respiratory distress syndrome. J Pathol 2004;202:145-156.
69. Bhatia M, Saluja AK, Singh VP, et al. Complement factor C5a exerts an anti-inflammatory effect in acute pancreatitis and associated lung injury. Am J Physiol Gastrointest Liver Physiol 2001;280: G974-G978.
70. Gerard C, Gerard NP. C5a anaphylatoxin and its seven transmembrane- segment receptor. Annu Rev Immunol 1994;12:775-808.
71. Bowden JJ, Garland AM, Baluk P, et al. Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc Natl Acad Sci USA 1994;91:8964-8968.
72. Bhatia M, Saluja AK, Hofbauer B, et al. Role of substance P and the neurokinin 1 receptor in acute pancreatitis and pancreatitis associated lung injury. Proc Natl Acad Sci USA 1998;95:4760-4765.
73. Vaquero E, Gukovsky I, Zaninovic V, et al. Localized pancreatic NF-kappaB activation and inflammatory response in taurocholate-induced pancreatitis. Am J Physiol Gastrointest Liver Physiol 2001; 280:G1197-G1208.
74. Luo JL, Kamata H, Karin M. IKK/NF-kappaB signaling: Balancing life and death - A new approach to cancer therapy. J Clin Invest 2005;115:2625-2632.
75. Zingarelli B. Nuclear factor-κB. Crit Care Med 2005; 33(12 Suppl):S414-S416.
76. Coimbra R, Melbostad H, Hoyt DB. Effects of phosphodiesterase inhibition on the inflammatory response after shock: Role of pentoxifylline. J Trauma 2004;56:442-449.
77. Gomez del Arco P, Martinez-Martinez S, Calvo V, et al. Antioxidants and AP-1 activation: A brief overview. Immunobiplogy 1997;198:273-278.
78. Karin M, Liu Z, Zandi E. AP-1 function and regulation. Curr Opin Cell Biol 1997;9:240-246.
79. Brady M, Christmas S, Sutton R, et al. Cytokines and acute pancreatitis. Baillieres Best Pract Res Clin Gastroenterol 1999;13:265-289.
80. Acioli JM, Isobe M, Kawasaki S. Early complement system activation and neutrophil priming in acute pancreatitis: Participation of trypsin. Surgery 1997; 122:909-917.
81. Fujimoto K, Hosotani R, Doi R, et al. Role of neutrophils in cerulein-induced pancreatitis in rats: Possible involvement of apoptosis. Digestion 1997;58:421-430.
82. Folch E, Closa D, Prats N, et al. Leukotriene generation and neutrophil infiltration after experimental acute pancreatitis. Inflammation 1998;22:83-93.
83. Witt DP, Lander AD. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 1994;4:394-400.
84. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 1994;76:301-314.
85. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines-CXC and CC chemokines. Adv Immunol 1994;55:97-179.
86. Tenner S, Sica G, Hughes M, et al. Relationship of necrosis to organ failure in severe acute pancreatitis. Gastroenterology 1997;113:899-903.
87. Muhs BE, Patel S, Yee H, et al. Inhibition of matrix metalloproteinases reduces local and distant organ injury following experimental acute pancreatitis. J Surg Res 2003;109:110-117.
88. Pitchumoni C, Agarwal N, Jain NK. Systemic complications, of acute pancreatitis. Am J Gastroenterol 1988;83:597-606.
89. Pastor CM, Matthay MA, Frossard JL. Pancreatitis-associated acute lung injury: New insights. Chest 2003;124:2341-2351.
90. Matthay MA, Zimmerman GA. Acute lung injury and the acute respiratory distress syndrome: Four decades of inquiry into pathogenesis and rational management. Am J Respir Cell Mol Biol 2005;33:319-327.
91. Shields CJ, Winter DC, Sookhai S, et al. Hypertonic saline attenuates end-organ damage in an experimental model of acute pancreatitis. Br J Surg 2000; 87:1336-1340.
92. Shields CJ, Sookhai S, Winter DC, et al. Attenuation of pancreatitis-induced pulmonary injury by aerosolized hypertonic saline. Surg Infect 2001;2:215-224.
93. Milani R Jr, Pereira PM, Dolhnikoff M, et al. Respiratory mechanics and lung morphometry in severe pancreatitis-associated acute lung injury in rats. Crit Care Med 1995,23:1882-1889.
94. O'Donovan DA, Kelly CJ, Abdih H, et al. Role of nitric oxide in lung injury associated with experimental acute pancreatitis. Br J Surg 1995;82:1122-1126.
95. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the adult respiratory distress syndrome. Clin Chest Med 1982;3:35-56.
96. Jaffray C, Yang J, Carter G, et al. Pancreatic elastase activates pulmonary nuclear factor kappa B and inhibitory kappa B, mimicking pancreatitis associated adult respiratory distress syndrome. Surgery 2000; 128:225-231.
97. 2 in human acute pancreatitis. Gastroenterology 1989;97:1521-1526
98. Simon RH, Paine R III. Participation of pulmonary alveolar epithelial cells in lung inflammation. J Lab Clin Med 1995;126:108-118.
99. Zhao X, Andersson R, Wang X, et al. Acute pancreatitis-associated lung injury: Pathophysiological mechanisms and potential future therapies. Scand J Gastroenterol 2002;37:1351-1358.
100. Wang XD, Borjesson A, Sun ZW, et al. The association of type II pneumocytes and endothelial permeability with the pulmonary custocyte system in experimental acute pancreatitis. Eur J Clin Invest 1998;28:778-785.
101. Mandi Y, Nagy Z, Ocsovski I, Farkas G. Effects of tumor necrosis factor and pentoxifylline on ICAM-1 expression on human polymorphonuclear granulocytes. Int Arch Allergy Immunol 1997;114:329-335.
102. Closa D, Sabater L, Fernandez-Cruz L, et al. Activation of alveolar macrophages in lung injury associated with experimental acute pancreatitis is mediated by the liver. Arm Surg 1999;229:230-236.
103. Kubo H, Morgenstern D, Quinian WM, et al. Preservation of complement induced lung injury in mice with deficiency of NADPH oxidase. J Clin Invest 1996;97:2680-2684.
104. Yan SR, Berton G. Antibody-induced engagement of beta2 integrins in human neutrophils causes a rapid redistribution of cytoskeletal proteins, Src-family tyrosine kinases, and p72syk that precedes de novo actin polymerization. J Leukoc Biol 1998,64:401-408.
105. Nick JA, Avdi NJ, Young SK, et al. Common and distinct intracellular signaling pathways in human neutrophils used by platelet activating factor and FMLP. J Clin Invest 1997,99:975-986.
106. Blackwell TS, Blackwell TR, Holden EP, et al. In vivo antioxidant treatment suppresses nuclear factor-kappa B activation and neutrophilic lung inflammation. J Immunol 1996;157:1630-1637.
107. Donnelly SC, Strieter RM, Kunkel SL, et al. Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993;341:643-646.
108. Keck T, Balcom JH 4th, Fernandez-del Castillo C, et al. Matrix metalloproteinase-9 promotes neutrophil migration and alveolar capillary leakage in pancreatitis-associated lung injury in the rat. Gastroenterology 2002;122:188-201.
109. Muhs BE, Patel S, Yee H, et al. Increased matrix metalloproteinase expression and activation following experimental acute pancreatitis. J Surg Res 2001;101:21-28.
110. Delclaux C, Delacourt C, D'Ortho MP, et al. Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol 1996;14:288-295.
111. Bassi C, Mangiante G, Falconi M, et al. Prophylaxis for septic complications in acute necrotizing pancreatitis. J Hepatobiliary Pancreat Surg 2001;8:211-215.
112. Dejong CH, Greve JW, Soeters PB. Nutrition in patients with acute pancreatitis. Curr Opin Crit Care 2001;7:251-256.
113. Yang CY, Chang-Chien CS, Liaw YF. Controlled trial of protease inhibitor gabexelate mesilate (FOY) in the treatment of acute pancreatitis. Pancreas 1987;2: 698-700.
114. Leese T, Holliday M, Heath D, et al. Multicentre clinical trial of low volume fresh frozen plasma therapy in acute pancreatitis. Br J Surg 1987;74:907-911.
115. Choi TK, Mok F, Zhan WH, et al. Somatostatin in the treatment of acute pancreatitis: A prospective randomised controlled trial. Gut 1989;30:223-227.
116. D'Amico D, Favia G, Biasiato R, et al. The use of somatostatin in acute pancreatitis: Results of a multicenter trial. Hepatogastroenterology 1990;37:92-98.
117. Harada H, Miyake H, Ochi K, et al. Clinical trial with a protease inhibitor gabexate mesilate in acute pancreatitis. Int J Pancreatol 1991;9:75-79.
118. Leese T, Holliday M, Watkins M, et al. A multicentre controlled clinical trial of high-volume fresh frozen plasma therapy in prognostically severe acute pancreatitis. Ann R Coll Surg Engl 1991;73:207-214.
119. Valderrama R, Perez-Mateo M, Navarro S, et al. Multicenter double-blind trial of gabexate mesylate (FOY) in unselected patients with acute pancreatitis. Digestion 1992;51:65-70.
120. Gjorup I, Roikjaer O, Andersen B, et al. A double-blinded multicenter trial of somatostatin in the treatment of acute pancreatitis. Surg Gynecol Obstet 1992;175:397-400.
121. Beechey-Newman N. Controlled trial of high-dose octreotide in treatment of acute pancreatitis: Evidence of improvement in disease severity. Dig Dis Sci 1993;38:644-647.
122. Buchler M, Malfertheiner P, Uhl W, et al. Gabexate mesilate in human acute pancreatitis. German Pancreatitis Study Group. Gastroenterology 1993;104: 1165-1170.
123. Pederzoli P, Cavallini G, Falconi M, Bassi C. Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.): A prospective, randomized, double-blind multicenter study. Int J Pancreatol 1993;14: 117-124.
124. Binder M, Uhl W, Friess H, et al. Octreotide in the treatment of acute pancreatitis: Results of a unicenter prospective trial with three different octreotide dosages. Digestion 1994;55(Suppl 1):20-23.
125. Luengo L, Vicente V, Gris F, et al. Influence of somatostatin in the evolution of acute pancreatitis: A prospective randomized study. Int J Pancreatol 1994;15:139-144.
126. Pederzoli P, Bassi C, Falconi M, et al. Gabexate mesilate in the treatment of acute pancreatitis. Ann Ital Chir 1995;66:191-195.
127. Kingsnorth AN, Galloway SW, Formela LJ. Randomized, double-blind phase II trial of lexipafant, a platelet-activating factor antagonist, in human acute pancreatitis. Br J Surg 1995;82:1414-1420.
128. McKay C, Baxter J, Imrie C. A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. Int J Pancreatol 1997; 21:13-19.
129. McKay CJ, Curran F, Sharples C, et al. Prospective placebo-controlled randomized trial of lexipafant in predicted severe acute pancreatitis. Br J Surg 1997; 84:1239-1243.
130. Planas M, Perez A, Iglesia R, et al. Severe acute pancreatitis: Treatment with somatostatin. Intensive Care Med 1998;24:37-39.
131. Uhl W, Buchler MW, Malfertheiner P, et al. A randomised, double blind, multicentre trial of octreotide in moderate to severe acute pancreatitis. Gut 1999;45:97-104.
132. Chen HM, Chen JC, Hwang TL, et al. Prospective and randomized study of gabexate mesilate for the treatment of severe acute pancreatitis with organ dysfunction. Hepatogastroenterology 2000;47:1147-1150.
133. Paran H, Mayo A, Paran D, et al. Octreotide treatment in patients with severe acute pancreatitis. Dig Dis Sci 2000;45:2247-2251.
134. Johnson CD, Kingsnorth AN, Imrie CW, et al. Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. Gut 2001;48:62-69.
135. Pezzilli R, Miglioli M. Multicentre comparative study of two schedules of gabexate mesilate in the treatment of acute pancreatitis. Italian Acute Pancreatitis Study Group. Dig Liver Dis 2001;33: 49-57.
136. Nikou GC, Arnaoutis TP, Giamarellos-Bourboulis EJ, et al. The significance of the dosage adjustment of octreotide in the treatment of acute pancreatitis of moderate severity. Hepatogastroenterology 2001;48: 1754-1757.
137. Du WD, Yuan ZR, Sun J, et al. Therapeutic efficacy of high-dose vitamin C on acute pancreatitis and its potential mechanisms. World J Gastroenterol 2003; 9:2565-2569.
138. Virlos IT, Mason J, Schofield D, et al. Intravenous N-acetylcysteine, ascorbic acid and selenium-based anti-oxidant therapy in severe acute pancreatitis. Scand J Gastroenterol 2003;38:1262-1267.
139. 2 in human serum and pancreatic juice. Dig Dis Sci 2005;50:868-873.
140. Seta T, Noguchi Y, Shimada T, et al. Treatment of acute pancreatitis with protease inhibitors: A meta-analysis. Eur J Gastroenterol Hepatol 2004;16:1287-1293.
141. Wu JX, Yuan YZ, Xu JY, et al. Changes in somatostatin receptor expression of the pancreas and effectiveness of octreotide in rats with acute necrotizing pancreatitis. Chin J Dig Dis 2004;5:35-39.
142. Cavallini G, Frulloni L. Somatostatin and octreotide in acute pancreatitis: The never-ending story. Dig Liver Dis 2001;33:192-201.
143. Machado MC, Coelho AM, Pontieri V, et al. Local and systemic effects of hypertonic solution (NaCl 7.5%) in experimental acute pancreatitis. Pancreas 2006;32:80-86.
144. Yada-Langui MM, Coimbra R, Lancellotti C, et al. Hypertonic saline and pentoxifylline prevent lung injury and bacterial translocation after hemorrhagic shock. Shock 2000;14:594-598.
145. Pereda J, Sabater L, Cassinello N, et al. Effect of simultaneous inhibition of TNF-alpha production and xanthine oxidase in experimental acute pancreatitis: The role of mitogen activated protein kinases. Ann Surg 2004;240:108-116.
146. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med 2000;342:1301-1308.